Biostem Technologies (BSEM) M&A announcement summary

Deal rationale and strategic fit

• Acquisition of BioTissue's surgical and wound care business doubles the addressable market, accelerates entry into acute wound care, and diversifies product offerings and revenue streams.

• Expands reach into both chronic and acute wound care markets, including hospital inpatient, outpatient, and ambulatory surgery centers, and strengthens presence in high-growth surgical and hospital-based markets.

• Complements legacy business with new technologies and product lines, aligning with long-term goals of diversification, portfolio expansion, and operational excellence.

• Integration of an experienced national sales force and access to major GPO networks accelerates commercial expansion and broadens national footprint.

• De-risks reimbursement exposure by diversifying payer mix and revenue streams, especially in light of CMS policy changes.

Financial terms and conditions

• Upfront cash payment of approximately $15 million for all purchased and licensed assets, with up to $10 million in regulatory milestone payments and up to $15 million in commercial royalty milestone payments.

• Acquired assets generated about $29 million in 2025 sales with industry-standard gross margins of 65%.

• Post-closing cash and equivalents balance is approximately $16 million.

• Additional regulatory milestone payment contingent on 510(k) clearance for a pipeline product.

• Potential royalty milestone payments equal to 7% of sales on acquired products, up to $15 million, starting after tech transfer of manufacturing.

Synergies and expected cost savings

• Integration of BioTissue's national sales force and GPO contracts immediately strengthens presence in hospital and surgical settings and enhances operational efficiency.

• Manufacturing and supply agreement with BioTissue for at least 12 months, after which products will be onboarded to in-house manufacturing, expected to expand gross margins.

• Combined product suite and technology platforms anticipated to create synergies and broaden market access.

• Anticipated operational synergies from vertically integrated manufacturing and expanded commercial capabilities.